Please try another search
Enzolytics, Inc. is a drug development biotechnology company. The Company is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The Company is focused on developing monoclonal antibody therapy and treating infectious diseases. It has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested anti-HIV therapeutics. The Company has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The Company has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The Company is testing these antibodies to prepare them for use as therapies against these diseases.
Name | Age | Since | Title |
---|---|---|---|
M. David Sayid | 64 | 2011 | Director |
Ronald B. Moss | 60 | 2020 | Member of Medical Advisory Board |
Suraj Kumar | - | 2022 | Member of Advisory Board |
Kirsten Bischof | - | 2022 | Member of Advisory Board |
Harry H. Zhabilov | 57 | 2009 | CSO & Chairman |
Joseph P. Cotropia | - | 2020 | Chief Medical Officer & Director |
Gaurav Chandra | - | - | COO & Director |
Lachezar Ivanov | - | 2024 | Director |
Charles S. Cotropia | - | 2020 | President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review